Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy

  • R Fledrich
  • T Abdelaal
  • L Rasch
  • V Bansal
  • V Schütza
  • B Brügger
  • C Lüchtenborg
  • T Prukop
  • J Stenzel
  • R U Rahman
  • D Hermes
  • D Ewers
  • W Möbius
  • T Ruhwedel
  • I Katona
  • J Weis
  • D Klein
  • R Martini
  • W Brück
  • W C Müller
  • S Bonn
  • I Bechmann
  • K A Nave
  • R M Stassart
  • M W Sereda


In patients with Charcot-Marie-Tooth disease 1A (CMT1A), peripheral nerves display aberrant myelination during postnatal development, followed by slowly progressive demyelination and axonal loss during adult life. Here, we show that myelinating Schwann cells in a rat model of CMT1A exhibit a developmental defect that includes reduced transcription of genes required for myelin lipid biosynthesis. Consequently, lipid incorporation into myelin is reduced, leading to an overall distorted stoichiometry of myelin proteins and lipids with ultrastructural changes of the myelin sheath. Substitution of phosphatidylcholine and phosphatidylethanolamine in the diet is sufficient to overcome the myelination deficit of affected Schwann cells in vivo. This treatment rescues the number of myelinated axons in the peripheral nerves of the CMT rats and leads to a marked amelioration of neuropathic symptoms. We propose that lipid supplementation is an easily translatable potential therapeutic approach in CMT1A and possibly other dysmyelinating neuropathies.

Bibliografische Daten

StatusVeröffentlicht - 02.08.2018
PubMed 30072689